Biologists often say that structure determines function. In a new study, Northwestern University researchers show that this principle applies not only to proteins but may also to cancer vaccines—where the nanoscale arrangement of a single peptide can dramatically alter therapeutic potency. By re‑engineering the orientation of an HPV‑derived antigen on a spherical nucleic acid (SNA) platform, the team created a vaccine that slowed tumor growth and extended survival in preclinical models of HPV‑driven cancer. The work, published in Science Advances and titled “E711‑19 Placement and Orientation Dictate CD8⁺ T Cell Response in Structurally Defined Spherical Nucleic Acid Vaccines,” explores how subtle architectural changes can reshape immune activation. HPV‑positive head and neck cancers, which are rising in incidence, often present at advanced stages and are treated with toxic regimens, according to the authors. While prophylactic HPV vaccines prevent infection, they do not help patients with established tumors—leaving a need for therapeutic strategies that can safely drive strong cytotoxic T‑cell responses. To address this, the researchers designed three SNA‑based vaccines containing identical components: a lipid core, CpG adjuvant, and a short HPV16 E711‑19 peptide. The only difference was how the antigen was displayed. One formulation buried the peptide inside the nanoparticle, while two others attached it to the surface through either the N‑terminus or C‑terminus—a small structural shift with potentially large immunological consequences. The differences were striking. All three SNAs enhanced dendritic cell activation and CD8⁺ T‑cell cytotoxicity compared to a simple peptide‑adjuvant mixture, but the N‑terminally displayed version, dubbed N‑HSNA, consistently…
